GSK plc vs Paychex, Inc. — how do they compare? GSK plc trades at $51.15 (market cap $102.60B), while Paychex, Inc. trades at $121.38 (market cap $43.14B). The key difference: GSK plc is far larger — about 2.4× Paychex, Inc.'s market cap, and Paychex, Inc. pays the higher dividend (3.92%). Which is the better fit depends on your goals.
| GSK | PAYX | |
|---|---|---|
Market Cap | $102.60B | $43.14B |
Sector | Health | Industrials |
52-Week High | $61.18 | $140.81 |
52-Week Low | $38.22 | $85.57 |
Enterprise Value | $123.04B | $46.63B |
Dividend Yield | 3.57% | 3.92% |
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Paychex (PAYX) trades at $120.34, down 0.69% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a 27.03% net income margin and consistent earnings beats, though valuation ratios like a P/E of 24.81 are elevated. Recent news highlights steady small business employment data and product expansion, supporting its core HR services business.
The outlook is mixed: solid fundamentals and dividend payments offer stability, but high valuation and analyst caution (63.33% hold rating) suggest limited near-term upside. Risks include economic sensitivity and debt levels, yet long-term growth in HR outsourcing remains a tailwind for patient investors.
Trailing returns across standard periods
Latest headlines on both assets
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →